[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014688:Venoms / Q000008:administration & dosage / Q000627:therapeutic use*; D015431:Weight Loss
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D008687:Metformin; D000077270:Exenatide; D005947:Glucose; D000068900:Sitagliptin Phosphate